Study to Investigate the Ability of [11C]Donepezil PET to Image the Parasympathetic Nervous System

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

7 participants

Study Classification

OBSERVATIONAL

Study Start Date

2013-05-31

Study Completion Date

2013-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

AIM: To validate the tracer \[11C\]donepezil for use in the parasympathetic nervous system.

MATERIALS AND METHODS: The Investigators will include 7 healthy males aged 45-75 in our study. The participants will receive a careful medical examination, including a neurological examination, as part of the inclusion process. The subjects also have an MRI scan of the brain. PET/CT scans with \[11C\]donepezil are conducted. Six subjects will receive two PET/CT scans - once for the upper abdominal region and once for the head region two evaluate dynamic binding characteristics of the tracer in internal organ. Additionally, one single subject will receive 5 consecutive whole body PET scans to estimate radioactive dosimetry of this tracer.

PERSPECTIVES: The study will potentially result in the development of a PET ligand for imaging the parasympathetic nervous system. This will have applications for research in Parkinson's disease, diabetes, heart disease and other disorders, in which the autonomic nervous system is involved

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

[11C]Donepezil PET For Imaging The Autonomous Nervous System In Parkinsons Disease

NCT02012595

Parkinson's Disease

COMPLETED

A Study of Brain Imaging With Nuclear Medicine Technology in Individuals With and at Risk for Parkinson's Disease

NCT00117819

Parkinsonian Syndrome

COMPLETED PHASE2

11C-PIB PET/CT in Patients With Parkinson's Disease and Parkinsonian Dementia Syndromes

NCT03555292

Parkinson Disease

UNKNOWN PHASE2

PharmacoMRI of Parkinson Disease

NCT01528592

Parkinson's Disease

COMPLETED NA

Assessing Imaging as a Tool in Monitoring and Predicting the Progression of Parkinson Disease

NCT00404170

Parkinson Disease

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Please see the published paper wherein all details are listed:

In vivo imaging of human acetylcholinesterase density in peripheral organs using 11C-donepezil: dosimetry, biodistribution, and kinetic analyses.

Gjerløff T, Jakobsen S, Nahimi A, Munk OL, Bender D, Alstrup AK, Vase KH, Hansen SB, Brooks DJ, Borghammer P. J Nucl Med. 2014 Nov;55(11):1818-24.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Parkinson's Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

[11C]donepezil PET

\[11C\]donepezil is a radiopharmaceutical. It is evaluated whether the binding of \[11C\]donepezil in various peripheral tissues is in accordance with known distribution of the parasympathetic nervous system.

[11C]donepezil PET

Intervention Type OTHER

Positron Emission Tomography (PET) imaging of acetylcholinesterase with the ligand \[11C\]donepezil

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

[11C]donepezil PET

Positron Emission Tomography (PET) imaging of acetylcholinesterase with the ligand \[11C\]donepezil

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* male
* 45-75 years

Exclusion Criteria

* dementia,
* psychiatric diseases,
* serious medical illness including any type of previous cancer, any drug with known interaction with the autonomic nervous system

Minimum Eligible Age

45 Years

Maximum Eligible Age

75 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes